Proactive Investors - Run By Investors For Investors

Redx Pharma CEO focused on driving fibrosis and oncology assets into the clinic

Lisa Anson, chief executive of Redx Pharma Plc (LON:REDX), caught up with Proactive London's Andrew Scott to discuss the group's preliminary results to September 2018 as well as the appointment of a new chief financial officer.

Anson says Redx is ready to begin first-in-man trials of lead oncology drug, RXC004, in the first half of next year.

Putative fibrosis treatment RXC006 is expected to enter the clinic the year after.

 
Meet Alliance Pharma plc, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full REDX profile View Profile

Redx Pharma Plc Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use